-11%

Larazotide Acetate (AT-1001) 10mg research peptide for intestinal permeability studies

Larazotide Acetate (AT-1001) | Tight Junction Regulator Peptide

Name: Larazotide Acetate (AT-1001) | Tight Junction Regulator Peptide - TITANFORGE LABS
Price: 89.00 USD
Availability: InStock

Original price was: $100.00.Current price is: $89.00.

Larazotide Acetate (AT-1001) is a synthetic eight-amino acid peptide that functions as a first-in-class zonulin antagonist. Specifically designed to regulate the “opening” of the intestinal barrier, Larazotide Acetate (AT-1001) is the primary subject of research involving pathological intestinal permeability (often termed “leaky gut”). In laboratory models, it is studied for its ability to prevent the disassembly of tight junctions triggered by gluten, cytokines, or environmental toxins.

Categories: COLLAGEN & RECOVERY PEPTIDES, GUT HEALTH AND MUCOSAL REPAIR Tags: AT-1001, Celiac Research, Intestinal Permeability, Larazotide Acetate, Leaky Gut., Tight Junctions, Zonulin Antagonist

Description
Reviews (0)

Larazotide Acetate (AT-1001): The Master Regulator of the Intestinal Barrier

The Biochemistry of the Zonulin Pathway

Larazotide Acetate (AT-1001) was derived from a sequence found in the Vibrio cholerae zonula occludens toxin. It acts by competitively inhibiting the zonulin receptor. Zonulin is the only known physiological modulator of intercellular tight junctions; when overexpressed, it causes the “gates” between enterocytes to remain open. Research into Larazotide Acetate (AT-1001) focuses on its ability to block this signaling, thereby maintaining the structural integrity of the paracellular pathway.

Mechanism of Action: Tight Junction Stabilization

In advanced mucosal immunology research, Larazotide Acetate (AT-1001) functions through highly targeted mechanisms:

Antagonizing Zonulin Signaling: Larazotide Acetate (AT-1001) prevents zonulin from binding to its target receptor (EGFR/PAR2), which would otherwise trigger the contraction of the perijunctional actin-myosin ring.
Preservation of Occludin and ZO-1: By inhibiting the zonulin pulse, Larazotide Acetate (AT-1001) ensures that key structural proteins like Occludin and Zonula Occludens-1 (ZO-1) remain correctly localized at the tight junction complex.
Prevention of Macromolecular Translocation: Research demonstrates that Larazotide Acetate (AT-1001) restricts the passage of large, immunogenic molecules (such as gliadin fragments or LPS) from the intestinal lumen into the systemic circulation.
Cytokine-Induced Barrier Protection: Beyond gluten-related studies, Larazotide Acetate (AT-1001) is investigated for its ability to counteract barrier disruption caused by pro-inflammatory cytokines like TNF-alpha and IFN-gamma.

[Image illustrating the difference between “open” and “closed” tight junctions via AT-1001]

Primary Research Applications of Larazotide Acetate (AT-1001)

Celiac Disease Models: Analyzing the peptide’s ability to prevent the inflammatory response to gluten ingestion.
Autoimmune Signaling: Investigating the link between intestinal permeability and the development of systemic autoimmune conditions.
Environmental Toxin Defense: Studying the protective effects of Larazotide Acetate (AT-1001) against glyphosate or heavy-metal induced barrier failure.
Inflammatory Bowel Disease (IBD): Observing the impact of tight junction stabilization on mucosal healing in colitis models.

4. Technical Specifications (E-E-A-T Data)

Feature	Scientific Specification
Peptide Sequence	Gly-Gly-Val-Leu-Ser-Glu-Leu-Tyr
Molecular Formula	$C_{36}H_{58}N_{8}O_{13}$
Molecular Weight	810.9 g/mol
CAS Number	881851-50-9
Purity Grade	$\geq$ 99% (HPLC & Mass Spec Verified)
Physical State	Lyophilized White Powder
Solubility	Soluble in Water and Aqueous Buffers

5. Product FAQ

Q: Is Larazotide Acetate (AT-1001) absorbed into the bloodstream?

A: A key characteristic of Larazotide Acetate (AT-1001) in research is its minimal systemic absorption. It is designed to act locally within the intestinal lumen and on the surface of the enterocytes, which is ideal for studying targeted gastrointestinal barrier regulation without systemic interference.

Q: How does AT-1001 differ from BPC-157 for gut health?

A: While both are studied for gut health, their mechanisms are distinct. Larazotide Acetate (AT-1001) is a specific tight junction regulator (zonulin antagonist), whereas BPC-157 is a broader regenerative peptide focused on angiogenesis and growth factor upregulation for tissue healing.